SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Henning Reis, Jeremias Wohlschläger, Sascha Hagemann, Patricia Wenzel, Lars P. Bechmann, Anna-Carinna Suttorp, Martin J. Schlattjan, Kerstin Herzer, Ali Canbay, Hideo A. Baba, (Cleaved) CK18 serum and tissue expression levels differentiate acute HCV reinfection from acute rejection in liver allografts, Liver International, 2015, 35, 3
  2. 2
    Pei-Wen Zhang, Feng-Xia Chen, Di Li, Wen-Hua Ling, Hong-Hui Guo, A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients With Nonalcoholic Fatty Liver Disease, Medicine, 2015, 94, 20, e758

    CrossRef

  3. 3
    H. H. Lutz, B. Schroeter, D. C. Kroy, U. Neumann, C. Trautwein, J. J. W. Tischendorf, Doppler Ultrasound and Transient Elastography in Liver Transplant Patients for Noninvasive Evaluation of Liver Fibrosis in Comparison with Histology: A Prospective Observational Study, Digestive Diseases and Sciences, 2015,

    CrossRef

  4. 4
    Nurdan Guldiken, Valentyn Usachov, Kateryna Levada, Christian Trautwein, Marianne Ziol, Pierre Nahon, Pavel Strnad, Keratins 8 and 18 are type II acute-phase responsive genes overexpressed in human liver disease, Liver International, 2015, 35, 4
  5. 5
    Diana M Toivola, Peter Boor, Catharina Alam, Pavel Strnad, Keratins in health and disease, Current Opinion in Cell Biology, 2015, 32, 73

    CrossRef

  6. 6
    Michael Fuchs, New Medical Treatment Strategies for Nonalcoholic Steatohepatitis, Current Treatment Options in Gastroenterology, 2015, 13, 2, 259

    CrossRef

  7. 7
    Davide Festi, Ramona Schiumerini, Giovanni Marasco, Eleonora Scaioli, Francesca Pasqui, Antonio Colecchia, Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives, Expert Review of Gastroenterology & Hepatology, 2015, 1

    CrossRef

  8. 8
    Ahilan Arulanandan, Rohit Loomba, Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?, Current Hepatology Reports, 2015,

    CrossRef

  9. 9
    Salvatore Petta, Ester Vanni, Elisabetta Bugianesi, Vito Di Marco, Calogero Cammà, Daniela Cabibi, Lavinia Mezzabotta, Antonio Craxì, The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease, Liver International, 2015, 35, 5
  10. 10
    Tom Luedde, Neil Kaplowitz, Robert F. Schwabe, Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance, Gastroenterology, 2014, 147, 4, 765

    CrossRef

  11. 11
    Keyur Patel, Nicholas A. Shackel, Current status of fibrosis markers, Current Opinion in Gastroenterology, 2014, 30, 3, 253

    CrossRef

  12. 12
    Petra Thulin, Gunnar Nordahl, Marcus Gry, Getnet Yimer, Eleni Aklillu, Eyasu Makonnen, Getachew Aderaye, Lars Lindquist, C. Mikael Mattsson, Björn Ekblom, Daniel J. Antoine, B. Kevin Park, Stig Linder, Alison H. Harrill, Paul B. Watkins, Björn Glinghammar, Ina Schuppe-Koistinen, Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts, Liver International, 2014, 34, 3
  13. 13
    E. Jaeckel, R. Taubert, M.P. Manns, Leber und Diabetes, Der Diabetologe, 2014, 10, 5, 405

    CrossRef

  14. 14
    Kenneth Cusi, Zhi Chang, Steve Harrison, Romina Lomonaco, Fernando Bril, Beverly Orsak, Carolina Ortiz-Lopez, Joan Hecht, Ariel E. Feldstein, Amy Webb, Christopher Louden, Martin Goros, Fermin Tio, Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease, Journal of Hepatology, 2014, 60, 1, 167

    CrossRef

  15. 15
    Peter Dietrich, Claus Hellerbrand, Non-alcoholic fatty liver disease, obesity and the metabolic syndrome, Best Practice & Research Clinical Gastroenterology, 2014, 28, 4, 637

    CrossRef

  16. 16
    J. K. Dyson, Q. M. Anstee, S. McPherson, Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging, Frontline Gastroenterology, 2014, 5, 3, 211

    CrossRef

  17. 17
    R. Anty, S. Patouraux, A. Tran, P. Gual, Obésité et maladie du foie gras non alcoolique, Obésité, 2014, 9, 4, 271

    CrossRef

  18. 18
    J. K. Dyson, S. McPherson, Q. M. Anstee, Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification, Postgraduate Medical Journal, 2014, 90, 1063, 254

    CrossRef

  19. 19
    Heike Bantel, Katharina John, Klaus Schulze-Osthoff, Robust Detection of Liver Steatosis and Staging of NAFLD by an Improved ELISA for Serum Cytokeratin-18 Fragments, The American Journal of Gastroenterology, 2014, 109, 1, 140

    CrossRef

  20. 20
    Jing Chen, Yueyong Zhu, Qi Zheng, Jiaji Jiang, Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis, Hepatology Research, 2014, 44, 8
  21. 21
    R. Kwok, Y.-K. Tse, G. L.-H. Wong, Y. Ha, A. U. Lee, M. C. Ngu, H. L.-Y. Chan, V. W.-S. Wong, Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments, Alimentary Pharmacology & Therapeutics, 2014, 39, 3
  22. 22
    Noa Mashav, Oren Shibolet, Liver Metabolism and Fatty Liver Disease, 2014,

    CrossRef

  23. 23
    Florian Puls, Imeke Goldschmidt, Heike Bantel, Clemens Agne, Verena Bröcker, Maximilian Dämmrich, Ulrich Lehmann, Jens Berrang, Eva-Doreen Pfister, Hans Heinrich Kreipe, Ulrich Baumann, Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease, Journal of Hepatology, 2013, 59, 3, 626

    CrossRef

  24. 24
    Oliver Waidmann, Verena Köberle, Dominik Bettinger, Jörg Trojan, Stefan Zeuzem, Michael Schultheiß, Bernd Kronenberger, Albrecht Piiper, Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma, Journal of Hepatology, 2013, 59, 4, 769

    CrossRef

  25. 25
    Hanan Abdel Haleem, Naglaa Zayed, Hanan Abdel Hafez, Ahmed Fouad, Maha Akl, Mona Hassan, Olfat Hammam, Abdellah Morsy, Azza Saleh, Moataz Seyam, Zeinab Zakaria, Soher Zakaria, Evaluation of the diagnostic value of serum and tissue apoptotic cytokeratin-18 in patients with chronic hepatitis C, Arab Journal of Gastroenterology, 2013, 14, 2, 68

    CrossRef

  26. 26
    Bryan D. Maliken, James E. Nelson, Heather M. Klintworth, Mary Beauchamp, Matthew M. Yeh, Kris V. Kowdley, Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease, Hepatology, 2013, 57, 5
  27. 27
    K John, S Wielgosz, K Schulze-Osthoff, H Bantel, R Hass, Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndrome, Cell Death and Disease, 2013, 4, 10, e886

    CrossRef

  28. 28
    J. K. Dyson, S. McPherson, Q. M. Anstee, Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification, Journal of Clinical Pathology, 2013, 66, 12, 1033

    CrossRef

  29. 29
    Albert Tran, Philippe Gual, Non-alcoholic steatohepatitis in morbidly obese patients, Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 1, 17

    CrossRef

  30. 30
    Froukje J. Verdam, Jan W. Dallinga, Ann Driessen, Charlotte de Jonge, Edwin J.C. Moonen, Joep B.N. van Berkel, Jakobus Luijk, Nicole D. Bouvy, Wim A. Buurman, Sander S. Rensen, Jan Willem M. Greve, Frederik Jan van Schooten, Non-alcoholic steatohepatitis: A non-invasive diagnosis by analysis of exhaled breath, Journal of Hepatology, 2013, 58, 3, 543

    CrossRef

  31. 31
    Mariana V. Machado, Helena Cortez-Pinto, Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal, Journal of Hepatology, 2013, 58, 5, 1007

    CrossRef

  32. 32
    Steven G Pearce, Nirav C Thosani, Jen-Jung Pan, Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD, Biomarker Research, 2013, 1, 1, 7

    CrossRef

  33. 33
    Jun Yu, Jiayun Shen, Ting Ting Sun, Xiang Zhang, Nathalie Wong, Obesity, insulin resistance, NASH and hepatocellular carcinoma, Seminars in Cancer Biology, 2013, 23, 6, 483

    CrossRef

  34. 34
    Steve Choi, Anna Mae Diehl, After goodbye? Dead hepatocytes as a biomarker for fibrosis and steatohepatitis, Hepatology, 2012, 55, 2
  35. You have free access to this content35
    J. Shen, H. L.-Y. Chan, G. L.-H. Wong, A. W.-H. Chan, P. C.-L. Choi, H.-Y. Chan, A. M.-L. Chim, D. K.-W. Yeung, J. Yu, W. C.-W. Chu, V. W.-S. Wong, Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers, Alimentary Pharmacology & Therapeutics, 2012, 36, 11-12
  36. 36
    H. H. Lutz, N. Gassler, F. W. Tischendorf, C. Trautwein, J. J. W. Tischendorf, Doppler Ultrasound of Hepatic Blood Flow for Noninvasive Evaluation of Liver Fibrosis Compared with Liver Biopsy and Transient Elastography, Digestive Diseases and Sciences, 2012, 57, 8, 2222

    CrossRef

  37. 37
    Dawn M. Torres, Christopher D. Williams, Stephen A. Harrison, Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease, Clinical Gastroenterology and Hepatology, 2012, 10, 8, 837

    CrossRef

  38. 38
    Nadia Ovchinsky, Roger K. Moreira, Jay H. Lefkowitch, Joel E. Lavine, Liver Biopsy in Modern Clinical Practice, Advances In Anatomic Pathology, 2012, 19, 4, 250

    CrossRef

  39. 39
    Jayashree Bagchi Chakraborty, Fiona Oakley, Meagan J. Walsh, Mechanisms and Biomarkers of Apoptosis in Liver Disease and Fibrosis, International Journal of Hepatology, 2012, 2012, 1

    CrossRef

  40. 40
    Geoffrey C. Farrell, Derrick van Rooyen, Lay Gan, Shivrakumar Chitturi, NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications, Gut and Liver, 2012, 6, 2, 149

    CrossRef

  41. 41
    Marten Heeringa, Ann Hastings, Shunji Yamazaki, Paul de Koning, Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?, Biomarkers in Medicine, 2012, 6, 6, 743

    CrossRef

  42. 42
    Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Non-Invasive Methods to Determine the Severity of NAFLD and NASH,
  43. 43
    Geoffrey C. Farrell, Arthur J. McCullough, Christopher P. Day, What is Non-Alcoholic Fatty Liver Disease (NAFLD), and Why is it Important?,